Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089 - PubMed (original) (raw)
Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089
H Huynh et al. Int J Oncol. 1998 Jul.
Abstract
Prostate cancer and benign prostate hyperplasia (BPH) are major public health problems. Prostate epithelial cell proliferation is regulated by insulin-like growth factor I (IGF-I) which is mitogenic and anti-apoptotic, and IGF binding protein 3 (IGFBP-3) which is an apoptotic agent in these cells. We demonstrate that the 1,25(OH)2D3 and its analog EB1089-induced growth inhibition was associated with increased IGFBP-3 mRNA abundance, IGFBP-3 mRNA stability, IGFBP-3 protein accumulation, and decreased IGF-II gene expression. Anti-IGF-II antibody and exogenous recombinant human IGFBP-3 inhibit PC-3 cell proliferation. The results document the inhibitory effects of 1,25(OH)2D3 and EB1089 on the IGF system of mitogens in prostate cancer cells, and suggest a potential therapeutic use of EB1089 in treatment of BPH and prostate cancer.
Similar articles
- Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.
Vink-van Wijngaarden T, Pols HA, Buurman CJ, Birkenhäger JC, van Leeuwen JP. Vink-van Wijngaarden T, et al. Eur J Cancer. 1996 May;32A(5):842-8. doi: 10.1016/0959-8049(95)00647-8. Eur J Cancer. 1996. PMID: 9081364 - Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3.
Sprenger CC, Peterson A, Lance R, Ware JL, Drivdahl RH, Plymate SR. Sprenger CC, et al. J Endocrinol. 2001 Sep;170(3):609-18. doi: 10.1677/joe.0.1700609. J Endocrinol. 2001. PMID: 11524241 - Vitamin D and the insulin-like growth factor system: Implications for colorectal neoplasia.
Ciulei G, Orasan OH, Coste SC, Cozma A, Negrean V, Procopciuc LM. Ciulei G, et al. Eur J Clin Invest. 2020 Sep;50(9):e13265. doi: 10.1111/eci.13265. Epub 2020 May 24. Eur J Clin Invest. 2020. PMID: 32379895 Review.
Cited by
- Vitamin D and cancer: a review of molecular mechanisms.
Fleet JC, DeSmet M, Johnson R, Li Y. Fleet JC, et al. Biochem J. 2012 Jan 1;441(1):61-76. doi: 10.1042/BJ20110744. Biochem J. 2012. PMID: 22168439 Free PMC article. Review. - Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells.
Vijayababu MR, Arunkumar A, Kanagaraj P, Arunakaran J. Vijayababu MR, et al. J Carcinog. 2006 Apr 6;5:10. doi: 10.1186/1477-3163-5-10. J Carcinog. 2006. PMID: 16600019 Free PMC article. - 1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest.
Washington MN, Kim JS, Weigel NL. Washington MN, et al. Prostate. 2011 Jan 1;71(1):98-110. doi: 10.1002/pros.21226. Prostate. 2011. PMID: 20632309 Free PMC article. - Potent 19-norvitamin D analogs for prostate and liver cancer therapy.
Kittaka A, Yoshida A, Chiang KC, Takano M, Sawada D, Sakaki T, Chen TC. Kittaka A, et al. Future Med Chem. 2012 Oct;4(16):2049-65. doi: 10.4155/fmc.12.130. Future Med Chem. 2012. PMID: 23157238 Free PMC article. Review. - Association Between Expression of Vitamin D Receptor and Insulin-Like Growth Factor 1 Receptor Among Breast Cancer Patients.
Alnimer A, Bhamidimarri PM, Talaat IM, Alkhayaal N, Eltayeb A, Ali N, Abusnana S, Hamoudi R, Bendardaf R. Alnimer A, et al. World J Oncol. 2023 Feb;14(1):67-74. doi: 10.14740/wjon1550. Epub 2023 Feb 26. World J Oncol. 2023. PMID: 36895995 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous